Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Abstract Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	María L. Formica, Hamoudi G. Awde Alfonso, Santiago D. Palma
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2021-04-01
Saila:	Pharmacology Research & Perspectives
Gaiak:	anti‐VEGF agent biological drugs nanoparticles ocular neovascularization
Sarrera elektronikoa:	https://doi.org/10.1002/prp2.723
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!